Format

Send to

Choose Destination
Biomed Res Int. 2013;2013:832404. doi: 10.1155/2013/832404. Epub 2013 Sep 23.

The fold variant BM4 is beneficial in a therapeutic Bet v 1 mouse model.

Author information

1
Christian Doppler Laboratory for Allergy Diagnosis and Therapy, University of Salzburg, 5020 Salzburg, Austria.

Abstract

BACKGROUND:

Specific immunotherapy using recombinant allergens is clinically effective; still wild-type allergens can provoke treatment-induced side effects and often show poor immunogenicity in vivo. Thus, we tested the low IgE-binding, highly immunogenic fold variant BM4 in a Bet v 1 mouse model.

METHODS:

Recombinant BM4 was used as active vaccine ingredient to treat mice sensitized to Bet v 1. As controls, mice were treated with either Bet v 1 or sham, and the humoral as well as cellular immune response was monitored. Moreover, lung function and lung inflammation were analysed.

RESULTS:

BM4 was more effective than wild-type Bet v 1 in inducing Bet v 1-specific blocking antibodies as well as IFN-γ and IL-10 producing T cells. Further, birch pollen induced lung inflammation could be ameliorated significantly by BM4 treatment as demonstrated by a reduction of airway hyperresponsiveness and drastically decreased eosinophil counts in bronchoalveolar lavage fluids.

CONCLUSION:

The study outlines the high potential of BM4 as vaccine candidate for the treatment of Bet v 1-mediated birch pollen allergies.

PMID:
24175303
PMCID:
PMC3794650
DOI:
10.1155/2013/832404
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center